Main uses of Allopurinol Teva

Allopurinol Teva is a medication primarily used to manage conditions associated with an excess of uric acid in the body. Uric acid is a waste product formed during the breakdown of purines, which are substances found naturally in the body and in certain foods. When levels of uric acid become too high, it can lead to the formation of crystals in tissues and joints.

Management of Gout

The most common use of this medication is for the long-term management of gout. Gout is a form of inflammatory arthritis characterized by the accumulation of urate crystals in the joints, causing pain, swelling, and redness. Allopurinol Teva works by reducing the production of uric acid, which helps prevent the formation of new crystals and allows existing deposits to gradually dissolve over time.

Prevention of Kidney Stones

Allopurinol Teva is used to prevent the recurrence of certain types of kidney stones. Patients who produce high levels of uric acid in their urine are at an increased risk of developing stones made of uric acid or calcium oxalate. By lowering uric acid concentrations, the medication reduces the likelihood of these stones forming in the urinary tract.

Hyperuricemia Related to Medical Treatments

This medication is also utilized to manage high uric acid levels (hyperuricemia) that may occur as a result of other medical treatments. For example, during certain cancer therapies, such as chemotherapy or radiation, large numbers of cells are broken down rapidly. This process releases significant amounts of purines into the bloodstream, which are then converted into uric acid. Allopurinol Teva helps maintain uric acid at manageable levels during these periods.

Benefits and Clinical Goals

The primary benefit of Allopurinol Teva is its ability to lower serum urate levels consistently. By addressing the underlying cause of crystal formation rather than just treating the symptoms, the medication aims to achieve several clinical goals:

• Reduction in Gout Flare Frequency: By keeping uric acid levels low, the frequency and severity of painful gout attacks are typically reduced.
• Prevention of Joint Damage: Long-term control of urate crystals helps protect joints from the chronic damage and deformity associated with untreated gout.
• Management of Tophaceous Gout: The medication can help shrink tophi, which are visible lumps of urate crystals that form under the skin or around joints in advanced cases.
• Kidney Protection: Lowering uric acid levels can help protect kidney function in individuals prone to urate-related renal complications.

Regulatory References

1. NIH MedlinePlus overview of Allopurinol

Eligibility and Contraindications

The eligibility for using Allopurinol Teva is strictly defined by official regulatory documentation.

The medicine is absolutely contraindicated and must not be used in individuals with a known hypersensitivity to allopurinol or a documented history of a severe reaction (such as SJS/TEN) to any formulation. Use is also prohibited for patients concomitantly receiving the drug didanosine.

---

Restricted or Conditional Use

Specific restrictions apply based on the patient's condition and physiological status:

• Condition-Based: The drug is not recommended for treating asymptomatic hyperuricemia alone, nor should therapy be initiated during an acute attack of gout.
• Organ Function: Use is restricted in patients with decreased renal or hepatic function, who require close management.
• Genetic Risk: Use is generally not recommended for carriers of the *HLA-B58:01 allele** due to increased risk of severe hypersensitivity, unless the benefits clearly outweigh the risks.

---

Population and Age Limitations

The medicine is approved for adults. However, pediatric use is strictly limited by regulatory labels to hyperuricemia associated with malignancy treatments (leukemia, lymphoma).

Regarding reproductive status, regulatory labels advise women not to breastfeed during therapy and state that use in pregnancy should occur only if clearly needed, due to the potential for fetal harm.

The regulatory information for Allopurinol Teva interactions is structured around severe co-administration restrictions, additive risks, and mandatory administration timing rules.

The most restrictive interaction involves Pegloticase; Allopurinol Teva must be formally discontinued and not initiated during co-administration of this drug. A major restriction exists with the cytotoxic agents Mercaptopurine and Azathioprine; their co-administration may lead to toxic levels with life-threatening myelosuppression. This interaction requires a mandated dose reduction of the cytotoxic agent to only one-quarter (25%) of the usual dose. Other exposure alterations involve Uricosuric agents, which are documented to increase the clearance of Allopurinol's active metabolite (oxipurinol). Allopurinol is also noted to increase the plasma concentration of Cyclosporine and enhance the anticoagulant effects of Warfarin.

The official label specifies an Additive Risk of Hypersensitivity when co-administered with Thiazide Diuretics, ACE Inhibitors, or Ampicillin/Amoxicillin, increasing the potential for developing a skin rash. This risk of severe hypersensitivity is officially noted to be further increased in patients with decreased renal function receiving Thiazide Diuretics. Finally, Aluminum-containing oral medications require a mandatory 3-hour separation of doses to prevent documented interference with Allopurinol absorption.

Enzyme Inhibition and Systemic Uric Acid Synthesis Blockade

The drug's mechanism initiates with the targeted inhibition of the enzyme Xanthine Oxidase (XO). Both the administered compound, Allopurinol, and its primary, longer-acting metabolite, Oxypurinol, bind to the enzyme's active site. Oxypurinol specifically forms a stable, complex bond with the enzyme's molybdenum center, acting as a time-dependent inhibitor. This activity results in a stable and sustained blockade of the enzyme's function. This selective blockade prevents the metabolic precursors, Hypoxanthine and Xanthine, from being converted into Uric Acid, resulting in a reduction of Uric Acid synthesis throughout the body.

Causal Chain to Hypouricemia and Physiological Clearance

The central physiological consequence of the enzyme blockade is a sustained state of hypouricemia (lowered Uric Acid concentration in the blood and tissues). The mechanism influences the body's Uric Acid pool by changing the composition of the excreted purine end-products. The sustained hypouricemia is the central physiological consequence. This creates a concentration gradient that facilitates the mobilization of Uric Acid from tissue deposits. Additionally, this mechanism reduces the formation of Reactive Oxygen Species (ROS) that are typically generated as byproducts of the Xanthine Oxidase reaction.

How to Use Allopurinol Teva — Official Administration Guidelines

Allopurinol Teva is primarily administered through the oral route as a tablet. The medicine is intended as part of a long-term management plan and its use is governed by a procedural sequence of dose initiation and adjustment.

Dosing and Titration

Therapy must commence at a low initial dosage, typically 100 mg once daily, followed by gradual titration in small increments, such as 100 mg weekly, until the target maintenance range is established. The maximum recommended daily dose for adults is typically 800 mg. Daily dosages exceeding 300 mg should be administered in divided doses to enhance gastrointestinal tolerability.

Administration Conditions

To minimize gastric irritation, tablets must be taken after a meal. An essential procedural requirement is the maintenance of high fluid intake to ensure a daily urinary output of at least two liters in adults. Administration must not be started during an acute gouty attack, but only after the attack has completely subsided. If a scheduled dose is missed, patients are instructed not to double the dose at the next scheduled time.

Population-Specific Rules

Dose modification is mandatory for specific patient groups. In cases of renal impairment, a significant reduction in the daily dosage is required due to reduced clearance of the active metabolite; for instance, severe kidney dysfunction necessitates 100 mg per day or longer dose intervals. Pediatric dosing (under 15 years) follows a mg/kg body weight-based regimen, up to a maximum of 400 mg daily.

Recent Clinical Evidence

Research has consistently examined allopurinol as a widely used treatment for reducing elevated serum uric acid (sUA) levels, a primary goal in managing gout and certain kidney stones. Studies focus on its mechanism as a xanthine oxidase inhibitor, which helps decrease the production of uric acid in the body.

---

Clinical Trial Data: Efficacy in Gout

Large-scale clinical trials and meta-analyses support allopurinol's role as a foundational therapy for chronic gout. The primary efficacy endpoint across most research is the achievement of target sUA levels, typically below 6.0 mg/dL.

• Long-Term Management: Research indicates that sustained use of allopurinol is associated with a lower frequency of gout flares over time and may contribute to the regression of tophi (uric acid deposits) in patients with severe gout.
• Mechanism of Action: Studies confirm that the compound's effect is due to its active metabolite, oxypurinol, which interferes with the enzyme xanthine oxidase. This action is the foundation of its intended use in hyperuricemia.

---

Safety and Tolerability Profiles

The safety profile of allopurinol has been extensively documented. Observational studies and trial data indicate that the compound is generally well-tolerated by most patients. However, serious adverse events, although rare, are detailed in public regulatory reports.

• Dose Initiation: Research highlights the importance of starting treatment at a low dose and gradually increasing it, a strategy often implemented to minimize the risk of hypersensitivity reactions, particularly in certain high-risk populations. The appropriate dose is determined by the patient's sUA levels and clinical response, as assessed by a healthcare provider.

Key Studies & References

1. Allopurinol for Secondary Prevention in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Common questions about Allopurinol Teva (FAQ)

Q: Do patients need to keep taking Allopurinol Teva even when they don't have gout symptoms?

A: The medicine is generally described in official product information as being intended for long-term management and preventive treatment of chronic gout and high uric acid levels. The goal is to maintain lower uric acid concentrations in the body over time. Therefore, use is typically continued even when acute symptoms are not present.

Q: Does Allopurinol Teva commonly cause stomach or digestive issues?

A: Regulatory documents indicate that common side effects can include nausea, vomiting, or diarrhea. Official guidance suggests taking the tablet after a meal to help enhance gastrointestinal tolerability.

Q: What signs of an allergic reaction should a patient look out for?

A: The official product labeling states that the first sign of a potentially serious reaction is often a skin rash, which may sometimes be followed by fever, sore throat, or swollen glands. Regulatory warnings state that patients should discontinue use at the first appearance of a skin rash or other signs of a hypersensitivity reaction, and seek immediate medical attention.

Q: Are there known food or supplement interactions with Allopurinol Teva?

A: Official information does not indicate specific interactions between allopurinol and foods or beverages. However, a specific interaction is noted with Aluminum-containing oral medications, which regulatory documents indicate the need for a 3-hour separation when taken to prevent interference with its absorption.

Q: Should I mention all my vitamins and supplements when discussing Allopurinol Teva with my doctor?

A: Regulatory guidance advises patients to inform their healthcare provider about all medicines they are taking. This comprehensive reporting includes prescription and over-the-counter (OTC) medicines, as well as herbal products, vitamins, and other dietary supplements.

Q: Is Allopurinol Teva a generic version of a different drug?

A: Allopurinol Teva is a brand name medicine that contains the active generic ingredient, allopurinol. The active ingredient, allopurinol, is the generic substance, which is offered under various brand names for the management of high uric acid.

Q: Does the 'Teva' part of the name mean anything specific about the medicine?

A: The 'Teva' part of the name refers to the pharmaceutical company that manufactures and distributes this particular preparation of the allopurinol tablet.

Q: Can someone take Allopurinol Teva with aspirin or other NSAIDs?

A: Official drug references and patient safety guidance indicate that a doctor may prescribe an NSAID (Nonsteroidal Anti-Inflammatory Drug) or colchicine as concurrent therapy in the early stages of Allopurinol Teva treatment. This is done to manage specific conditions during therapy initiation.

Q: Is alcohol generally prohibited when using Allopurinol Teva?

A: It is not known if drinking alcohol will directly affect how allopurinol works in the body. However, the use of alcohol may increase the risk of experiencing certain side effects such as dizziness or drowsiness.

Q: Can elderly patients take Allopurinol Teva safely?

A: Official product information states that dose adjustment may be necessary for older patients due to the higher prevalence of decreased renal function in this age group. Reduced kidney function is a factor that requires careful medication management.

Q: How long does it usually take for Allopurinol Teva to start working?

A: According to patient information, it may take between two to six weeks before changes in symptoms or blood test results begin to appear. Allopurinol is designed for sustained action in managing uric acid levels over the long term.

Q: Why does my gout sometimes get worse when I first start Allopurinol Teva?

A: Official documents state that an increase in gout attacks may occur during the initiation of treatment. Official guidelines recommend concurrent prophylactic treatment to help manage the possibility of increased gout attacks during therapy initiation.

Q: Does Allopurinol Teva cause fatigue or tiredness?

A: Official safety information lists drowsiness, somnolence, and dizziness as possible side effects. Furthermore, unusual tiredness is noted as a symptom that may be associated with more serious conditions such as blood disorders or kidney damage, requiring clinical evaluation.

How to Store and Dispose of Allopurinol Teva

Allopurinol tablets must be stored according to official regulatory requirements to maintain product stability and safety. The medication is classified as requiring Controlled Room Temperature storage, specifically not above 25 C (77 F).

Storage Conditions

Requirement	Specification
Temperature	Not above 25 C (Avoid freezing)
Protection	Store away from excess moisture and light
Container	Keep in the original container and keep it tightly closed
Child Safety	Must be kept out of the sight and reach of children

Disposal

Unused or expired tablets should be disposed of via an official drug take-back program or mail-back envelope when available. If not, the medicine must be mixed with an undesirable substance (e.g., dirt) in a sealed bag and thrown into the household trash, in accordance with local regulations. The product must not be flushed down the toilet or discharged into drains.